Filtered By:
Source: Diabetes, Obesity and Metabolism
This page shows you your search results in order of date.
Order by Relevance | Date
Total 82 results found since Jan 2013.
The Impact of Metformin Use on the Cardiovascular Effects of DPP ‐4 Inhibitors: an Analysis of Medicare Claims Data 2007‐2015
ConclusionsIncidence rate differences in multiple cardiovascular outcomes appeared more favorable when DPP ‐4i initiation occurred in the presence of metformin, suggesting a possible interaction between DPP‐4i and metformin.This article is protected by copyright. All rights reserved.
Source: Diabetes, Obesity and Metabolism - November 20, 2018 Category: Endocrinology Authors: Matthew J. Crowley,
Mugdha Gokhale,
Virginia Pate,
Til St ürmer,
John B. Buse Tags: ORIGINAL ARTICLE Source Type: research
Risk of coronary artery disease and stroke according to sex and presence of diabetic nephropathy in type 1 diabetes
Diabetes, Obesity and Metabolism,Volume 0, Issue ja, -Not available-.
Source: Diabetes, Obesity and Metabolism - July 2, 2018 Category: Endocrinology Authors: Valma
Harjutsalo
PhD
,
Merlin C
Thomas
MBChB, PhD, FRACP
,
Carol
Forsblom
DMSc
,
Per ‐Henrik
Groop
MD, DMSc, FRCPE
, Source Type: research
Impact of treatment with pioglitazone on stroke outcomes: A real ‐world database analysis
Diabetes, Obesity and Metabolism, EarlyView.
Source: Diabetes, Obesity and Metabolism - June 4, 2018 Category: Endocrinology Authors: Christopher Ll
Morgan
MSc
,
Silvio E.
Inzucchi
MD
,
Jorge
Puelles
MSc
,
Sara
Jenkins ‐Jones
MSc
,
Craig J.
Currie
PhD Source Type: research
Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2 ‐inhibitors versus other glucose‐lowering agents in real‐world clinical practice: Results from the CVD‐REAL study
Diabetes, Obesity and Metabolism, EarlyView.
Source: Diabetes, Obesity and Metabolism - April 17, 2018 Category: Endocrinology Authors: Mikhail
Kosiborod
MD
,
K åre I.
Birkeland
MD
,
Matthew A.
Cavender
MD
,
Alex Z.
Fu
PhD
,
John P.
Wilding
MD
,
Kamlesh
Khunti
MD
,
Reinhard W.
Holl
MD
,
Anna
Norhammar
MD
,
Marit E.
Jørgensen
MD
,
Eric T.
Wittbrodt
Ph Source Type: research
SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta ‐analysis
Diabetes, Obesity and Metabolism, EarlyView.
Source: Diabetes, Obesity and Metabolism - April 17, 2018 Category: Endocrinology Authors: Man
Guo
MD
,
Jingya
Ding
MD
,
Jingsong
Li
MD
,
Jiying
Wang
MD
,
Ting
Zhang
MD
,
Cuiping
Liu
MD
,
Wei
Huang
MD
,
Yang
Long
PhD
,
Chenlin
Gao
MD
,
Yong
Xu
MD Source Type: research
Effect of Intensive Blood Pressure Control in Patients with Type 2 Diabetes Mellitus Over 9 Years of Follow ‐Up: A Subgroup Analysis of High‐Risk ACCORDION Trial Participants
Abstract
Although guidelines recommend strict blood pressure (BP) control in patients with type 2 diabetes mellitus (T2DM) and elevated cardiovascular risk, the long‐term effects of this approach are unknown. We investigated the effect of intensive BP control on clinical outcomes in patients with T2DM over 9 years of follow‐up. We included ACCORD BP participants in the standard glucose control arm who had established cardiovascular disease, chronic kidney disease, age ≥75 years or 10‐year coronary heart risk ≥15%. Participants were randomized to either intensive (systolic BP <120 mm Hg) or standard (systolic B...
Source: Diabetes, Obesity and Metabolism - February 9, 2018 Category: Endocrinology Authors: Leo F. Buckley, Dave L. Dixon, George F. Wohlford, Dayanjan S. Wijesinghe, William L. Baker, Benjamin W. Van Tassell Tags: BRIEF REPORT Source Type: research
Have we really demonstrated the cardiovascular safety of anti ‐hyperglycaemic drugs? Rethinking the concepts of macrovascular and microvascular disease in type 2 diabetes
A primary goal of the treatment of type 2 mellitus is the prevention of morbidity and mortality associated with cardiovascular disease; however, anti‐hyperglycaemic drugs have the capacity to cause deleterious effects on the circulation, a risk that is not adequately reflected by the endpoints selected for emphasis in large‐scale clinical trials that are designed to evaluate cardiovascular safety. The primary endpoint of the large‐scale studies mandated by regulatory authorities focuses only on 3 to 4 events that depict only a limited view of the circulatory system. One of the most serious adverse effects of many glu...
Source: Diabetes, Obesity and Metabolism - February 4, 2018 Category: Endocrinology Authors: Milton Packer Tags: REVIEW ARTICLE Source Type: research
Plasma proprotein ‐convertase‐subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes
ConclusionsWe found that PCSK9 was inconsistently associated with CV events in populations with type 2 diabetes. The association may depend on the level of CV risk and the background treatment.
Source: Diabetes, Obesity and Metabolism - January 14, 2018 Category: Endocrinology Authors: Petra El Khoury, Ronan Roussel, Frederic Fumeron, Yara Abou ‐Khalil, Gilberto Velho, Kamel Mohammedi, Marie‐Paule Jacob, Philippe Gabriel Steg, Louis Potier, Youmna Ghaleb, Sandy Elbitar, Stephanie Ragot, Francesco Andreata, Giusepinna Caligiuri, Samy Tags: ORIGINAL ARTICLE Source Type: research
Have We Really Demonstrated the Cardiovascular Safety of Antihyperglycemic Drugs? Rethinking the Concepts of Macrovascular and Microvascular Disease in Type 2 Diabetes
Abstract
A primary goal of the treatment of type 2 mellitus is the prevention of morbidity and mortality due to cardiovascular disease. However, antihyperglycemic drugs have the capacity to cause deleterious effects on the circulation, a risk that is not adequately reflected by the endpoints selected for emphasis in large‐scale clinical trials that are designed to evaluate cardiovascular safety. The primary endpoint of the large‐scale studies mandated by regulatory authorities focuses only on 3‐4 events that depict only a limited view of the circulatory system.
One of the most serious adverse effects of many glucose...
Source: Diabetes, Obesity and Metabolism - January 5, 2018 Category: Endocrinology Authors: Milton Packer Tags: REVIEW ARTICLE Source Type: research
Plasma PCSK9 and Cardiovascular Events in Type 2 Diabetes
ConclusionsPCSK9 is inconsistently associated with CV events in populations with T2DM. The association may depend on the level of CV risk and the background treatment
Source: Diabetes, Obesity and Metabolism - December 5, 2017 Category: Endocrinology Authors: Petra El Khoury, Ronan Roussel, Frederic Fumeron, Yara Abou ‐Khalil, Gilberto Velho, Kamel Mohammedi, Marie‐Paule Jacob, P. Gabriel Steg, Louis Potier, Youmna Ghaleb, S El Bitar, S Ragot, Francesco Andreata, Giusepinna Caligiuri, Samy Hadjadj, Catheri Tags: ORIGINAL ARTICLE Source Type: research
High ‐sensitivity C‐reactive protein, low‐density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial
ConclusionsLevels of hsCRP were associated with recurrent cardiovascular events in patients with type 2 diabetes and recent acute coronary syndrome, and this association appears to be independent of and additive to the achieved LDL‐C level.
Source: Diabetes, Obesity and Metabolism - November 21, 2017 Category: Endocrinology Authors: You ‐Cheol Hwang, David A. Morrow, Christopher P. Cannon, Yuyin Liu, Richard Bergenstal, Simon Heller, Cyrus Mehta, William Cushman, George L. Bakris, Faiez Zannad, William B. White Tags: ORIGINAL ARTICLE Source Type: research
Metformin for the Management of Peri ‐operative Hyperglycemia
Perioperative hyperglycemia is an all too common issue (incidence 20‐40%) associated with significant surgical morbidity and mortality [1]. Often defined as a blood glucose >11.1mmol/L, peri‐operative hyperglycemia increases the risk for developing costly surgical site infections, sepsis, impairs wound healing, promotes endothelial dysfunction, thrombus formation, myocardial ischemia, stroke, neurocognitive dysfunction, prolongs length of hospitalization, and even death [2‐7].
Source: Diabetes, Obesity and Metabolism - November 9, 2017 Category: Endocrinology Authors: Russell Brown, James Paul Tags: LETTER TO THE EDITOR Source Type: research
High ‐sensitivity C‐reactive Protein, Low‐Density Lipoprotein Cholesterol, and Cardiovascular Outcomes in Patients with Type 2 Diabetes in the EXAMINE (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care) Trial
ConclusionsLevels of hsCRP were associated with recurrent cardiovascular events in patients with type 2 diabetes and recent acute coronary syndrome, and this association appears to be independent of and additive to the achieved LDL‐C level.Clinical trials registration number: NCT00968708
Source: Diabetes, Obesity and Metabolism - October 24, 2017 Category: Endocrinology Authors: You ‐Cheol Hwang, David A. Morrow, Christopher P. Cannon, Yuyin Liu, Richard Bergenstal, Simon Heller, Cyrus Mehta, William Cushman, George L Bakris, Faiez Zannad, William B White Tags: ORIGINAL ARTICLE Source Type: research
Influence of Metabolic Syndrome and Race on the Relationship between Intensive Blood Pressure Control and Cardiovascular Outcomes in the SPRINT Cohort
ConclusionsIn this analysis the CV benefit of intensive SBP control did not differ among subjects by baseline MetS status, regardless of race/ethnicity.
Source: Diabetes, Obesity and Metabolism - October 12, 2017 Category: Endocrinology Authors: Kathleen Dungan, Timothy E. Craven, Kyaw Soe, Jackson T. Wright, Jan Basile, William E. Haley, Nancy R. Kressin, Uzma Rani, Leonardo Tamariz, Jeff Whittle, Alan Wiggers, Kwame Osei Tags: ORIGINAL ARTICLE Source Type: research
Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials
The objective was to evaluate whether cardiovascular risk was increased with liraglutide treatment. The primary composite outcome of this time‐to‐event analysis was the first occurrence of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke. These cardiovascular events were adjudicated prospectively for three of the trials and retrospectively for two trials by an event adjudication committee. The primary outcome was analyzed using a Cox proportional hazards model, stratified by trial. With liraglutide 3.0 mg, 8 participants had positively adjudicated cardiovascular events (1.54 events/1000 person‐...
Source: Diabetes, Obesity and Metabolism - September 26, 2017 Category: Endocrinology Authors: MJ Davies, LJ Aronne, ID Caterson, AB Thomsen, PB Jacobsen, SP Marso, Tags: BRIEF REPORT Source Type: research
